Angela Casbard

2.6k total citations
52 papers, 1.8k citations indexed

About

Angela Casbard is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Angela Casbard has authored 52 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 10 papers in Surgery. Recurrent topics in Angela Casbard's work include Blood transfusion and management (7 papers), Blood groups and transfusion (6 papers) and Blood donation and transfusion practices (5 papers). Angela Casbard is often cited by papers focused on Blood transfusion and management (7 papers), Blood groups and transfusion (6 papers) and Blood donation and transfusion practices (5 papers). Angela Casbard collaborates with scholars based in United Kingdom, Australia and United States. Angela Casbard's co-authors include Michael Murphy, Claudia Turner, M Alison Metcalfe, Klim McPherson, James Hargreaves, Stephen Bridgman, Gareth Griffiths, M. Maresh, James G. Dobbins and C. Overton and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Angela Casbard

49 papers receiving 1.7k citations

Peers

Countries citing papers authored by Angela Casbard

Since Specialization

Citations

This map shows the geographic impact of Angela Casbard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Angela Casbard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Angela Casbard more than expected).

Fields of papers citing papers by Angela Casbard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Angela Casbard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Angela Casbard. The network helps show where Angela Casbard may publish in the future.

Co-authorship network of co-authors of Angela Casbard

This figure shows the co-authorship network connecting the top 25 collaborators of Angela Casbard. A scholar is included among the top collaborators of Angela Casbard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Angela Casbard. Angela Casbard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Mapping the pathway and support offered to children with an intellectual disability referred to specialist mental health services in the UK 2024 ·BJPsych Bulletin ·Vasiliki Totsika, (unknown), (unknown), (unknown), Angela Hassiotis, Eilis Kennedy, Michael Absoud, Rachel McNamara, Elizabeth Randell, (unknown), (unknown), Angela Casbard, (unknown), (unknown), (unknown), (unknown), Ashley Liew	0
2	HIDDEN2: Study protocol for the hospital deep vein thrombosis detection study in patients with cancer receiving palliative care 2023 ·BMJ Open ·(unknown), (unknown), Simon Noble, Nikki Pease, Raza Alikhan, Catherine Bryant, (unknown), Rebecca Wallace, Sarah Walker, Kathy Seddon, Deb Smith, Larry Raisanen, Joanna Smith, Ian Thomas, (unknown), Angela Casbard	1
3	Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial 2022 ·The Lancet Oncology ·Sacha J. Howell, Angela Casbard, Margherita Carucci, Kate Ingarfield, Rachel Butler, Siân Morgan, (unknown), C. Bale, Pavel Bezecny, (unknown), Chris Twelves, Ramachandran Venkitaraman, Simon Waters, Elza C. de Bruin, Gaia Schiavon, Andrew Foxley, Robert H. Jones	87
4	Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial 2022 ·EClinicalMedicine ·Dean A. Fennell, (unknown), J.F. Lester, Sarah Danson, Paul Taylor, Michael Sheaff, Robin Rudd, Aarti Gaba, Sara Busacca, Lisette Nixon, (unknown), Liz Darlison, Charlotte Poile, Cathy Richards, (unknown), Gareth Griffiths, Angela Casbard	17
5	Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial 2020 ·The Lancet Oncology ·Robert H. Jones, Angela Casbard, Margherita Carucci, Catrin Cox, Rachel Butler, Fouad Alchami, Tracie‐Ann Madden, C. Bale, Pavel Bezecny, Johnathan Joffe, (unknown), Chris Twelves, Ramachandran Venkitaraman, Simon Waters, Andrew Foxley, Sacha J. Howell	159
6	Why do patients decline surgical trials? Findings from a qualitative interview study embedded in the Cancer Research UK BOLERO trial (Bladder cancer: Open versus Lapararoscopic or RObotic cystectomy) 2016 ·Trials ·(unknown), Emily Harrop, John D. Kelly, Gareth Griffiths, Angela Casbard, Annmarie Nelson	34
7	SUCCINCT: An Open-label, Single-arm, Non-randomised, Phase 2 Trial of Gemcitabine and Cisplatin Chemotherapy in Combination with Sunitinib as First-line Treatment for Patients with Advanced Urothelial Carcinoma 2014 ·European Urology ·T. Geldart, John Chester, Angela Casbard, Simon J. Crabb, Tony Elliott, Andrew Protheroe, Robert Huddart, Graham M. Mead, Jim Barber, Robert J. Jones, Joanna Smith, (unknown), Jessica Evans, Gareth Griffiths	27
8	Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial 2013 ·The Lancet Oncology ·Peter Barrett‐Lee, Angela Casbard, Jacinta Abraham, Kerenza Hood, Robert E. Coleman, Peter Simmonds, (unknown), Duncan Wheatley, Robert Grieve, Gareth Griffiths, (unknown)	83
9	Prognostic significance of hypoxia inducible factor-1α and vascular endothelial growth factor expression in patients with diffuse large B-cell lymphoma treated with rituximab 2012 ·Leukemia & lymphoma ·J. Powell, Stefan Dojcinov, Louise King, (unknown), Stephen Gerry, Angela Casbard, (unknown), Eve Gallop‐Evans, Tim Maughan	9
10	A randomised controlled trial to compare minimally invasive glucose monitoring devices with conventional monitoring in the management of insulin-treated diabetes mellitus (MITRE) 2009 ·Health Technology Assessment ·Stanton Newman, Debbie Cooke, Angela Casbard, Simon Walker, Sarah Meredith, Andrew Nunn, Leigh Steed, Andrea Manca, Mark Sculpher, Maria Barnard, David Kerr, J. Weaver, James Ahlquist, (unknown)	16
11	Randomized controlled trial to assess the impact of continuous glucose monitoring on HbA_1c in insulin‐treated diabetes (MITRE Study) 2009 ·Diabetic Medicine ·Debbie Cooke, Steven J. Hurel, Angela Casbard, Leigh Steed, Simon Walker, Sarah Meredith, Andrew Nunn, Andrea Manca, Mark Sculpher, Maria Barnard, David Kerr, J. Weaver, James Ahlquist, Stanton Newman	30
12	The EASTR Study: indications for transfusion and estimates of transfusion recipient numbers in hospitals supplied by the National Blood Service 2009 ·Transfusion Medicine ·A. W. Wells, C. A. Llewelyn, Angela Casbard, (unknown), (unknown), S. Ballard, Jackie Buck, (unknown), Mike Murphy, L. M. Williamson	60
13	The impact of universal leukodepletion of the blood supply on hemovigilance reports of posttransfusion purpura and transfusion‐associated graft‐versus‐host disease 2007 ·Transfusion ·Lorna M. Williamson, D. Stainsby, Hilary Jones, Elizabeth M. Love, C. Chapman, Cristina Navarrete, Geoff Lucas, (unknown), Angela Casbard, Hannah Cohen, (unknown)	71
14	Silent myocardial ischaemia and haemoglobin concentration: a randomized controlled trial of transfusion strategy in lower limb arthroplasty 2006 ·Vox Sanguinis ·(unknown), Sumedh Talwalkar, Angela Casbard, H. Boralessa, (unknown), Stephen J. Brett, D. R. Goldhill, N. Soni	89
15	Feasibility and usefulness of self‐assessment of bleeding in patients with haematological malignancies, and the association between platelet count and bleeding 2006 ·Vox Sanguinis ·Simon Stanworth, Claire Dyer, Angela Casbard, Michael Murphy	16
16	End‐to‐end electronic control of the hospital transfusion process to increase the safety of blood transfusion: strengths and weaknesses 2006 ·Transfusion ·Amanda Davies, Julie Staves, Jonathan Kay, Angela Casbard, Michael Murphy	61
17	Accuracy of platelet counting haematology analysers in severe thrombocytopenia and potential impact on platelet transfusion 2005 ·British Journal of Haematology ·Helen Segal, Carol Briggs, S. Kunka, Angela Casbard, Paul Harrison, Samuel J. Machin, Michael Murphy	98
18	Severe Complications of Hysterectomy: The VALUE Study 2004 ·Obstetrical & Gynecological Survey ·Klim McPherson, M Alison Metcalfe, (unknown), M Maresh, Angela Casbard, James Hargreaves, (unknown), (unknown)	11
19	Sociology and behaviour of West African blood donors: the impact of religion on human immunodeficiency virus infection 2004 ·Vox Sanguinis ·J P Allain, (unknown), Angela Casbard, Shirley Owusu‐Ofori, (unknown)	13
20	Severe complications of hysterectomy: the VALUE study 2004 ·BJOG An International Journal of Obstetrics & Gynaecology ·Klim McPherson, M Alison Metcalfe, (unknown), M Maresh, Angela Casbard, James Hargreaves, Stephen Bridgman, Aileen Clarke	122

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact